BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20694463)

  • 1. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
    Poisson T; Deandreis D; Leboulleux S; Bidault F; Bonniaud G; Baillot S; Aupérin A; Al Ghuzlan A; Travagli JP; Lumbroso J; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2277-85. PubMed ID: 20694463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma.
    Zhai G; Zhang M; Xu H; Zhu C; Li B
    J Endocrinol Invest; 2010 Mar; 33(3):151-5. PubMed ID: 19783895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?
    Zoller M; Kohlfuerst S; Igerc I; Kresnik E; Gallowitsch HJ; Gomez I; Lind P
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):487-95. PubMed ID: 17103166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
    Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
    J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
    Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
    Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
    Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of FDG uptake in the arterial wall as an imaging biomarker of atherosclerotic plaques with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT).
    Bucci M; Aparici CM; Hawkins R; Bacharach S; Schrek C; Cheng S; Tong E; Arora S; Parati E; Wintermark M
    J Neuroimaging; 2014; 24(2):117-23. PubMed ID: 22928741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
    Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
    Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
    Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
    Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.
    Leboulleux S; Dromain C; Bonniaud G; Aupérin A; Caillou B; Lumbroso J; Sigal R; Baudin E; Schlumberger M
    J Clin Endocrinol Metab; 2006 Mar; 91(3):920-5. PubMed ID: 16368753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity.
    Biermann M; Kråkenes J; Brauckhoff K; Haugland HK; Heinecke A; Akslen LA; Varhaug JE; Brauckhoff M
    Acta Radiol; 2015 Nov; 56(11):1350-60. PubMed ID: 25770086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.